Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 15/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | STAT1 | P42224 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3634687 | 1.00 | QPCT (0.84) | QPCTKMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL3632304 | 1.00 | QPCT (0.84) | QPCTKMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL3633558 | 0.86 | QPCT (0.83) | QPCTKMT2APOLBNPC1RAB9A | |
| SCHEMBL3629554 | 0.86 | QPCT (0.81) | QPCTKMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL3629704 | 0.80 | QPCT (0.81) | QPCTKMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL3633668 | 0.79 | QPCT (0.84) | QPCTKMT2AALDH1A1MAOAMAOB | |
| SCHEMBL3633490 | 0.78 | QPCT (0.82) | QPCTKMT2AMAPT | |
| SCHEMBL3632425 | 0.77 | QPCT (0.84) | QPCTPOLBKDM4EALDH1A1MAPT | |
| SCHEMBL14012414 | 0.77 | QPCT (1.00) | QPCTKMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL3633397 | 0.76 | QPCT (0.81) | QPCTKMT2AKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656991-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2017-05-23 | — | — | US | disclosed |
| US-9656991-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2017-05-23 | — | — | US | disclosed |
| EP-2865670-B1 | Thiourea derivatives as glutaminyl cyclase inhibitors | PROBIODRUG AG (DE) | 2017-01-11 | — | — | EP | disclosed |
| EP-2865670-A1 | Thiourea derivatives as glutaminyl cyclase inhibitors | Probiodrug AG (DE) | 2015-04-29 | — | — | EP | disclosed |
| US-20080286231-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-11-20 | — | — | US | disclosed |
| US-20080286231-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-11-20 | — | — | US | disclosed |
| WO-2008128985-A1 | THIOUREA DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080286231-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, QPCT | QPCT 3/4885KMT2A 2652/4885POLB 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.